Scholar Rock is a late-stage global biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. They are a global leader in myostatin biology, with a commitment to unlocking fundamentally different treatment approaches, powered by the application of a proprietary platform.
Drive patient identification and market development for SMA by building and executing against a territory strategy, account and customer specific plans thereby achieving and exceeding sales goals.
Continuously assesses sales opportunities within markets and accounts to maintain and grow their business.
Educate and connect HCPs to Scholar Rock services.